NASDAQ:PAHC - Phibro Animal Health Stock Price, Forecast & News

Phibro Animal Health trades on the NASDAQ under the ticker symbol "PAHC."

Phibro Animal Health announced a quarterly dividend on Monday, November 4th. Shareholders of record on Wednesday, November 27th will be given a dividend of $0.12 per share on Wednesday, December 18th. This represents a $0.48 dividend on an annualized basis and a dividend yield of 1.86%. The ex-dividend date of this dividend is Tuesday, November 26th. View Phibro Animal Health's Dividend History.

Phibro Animal Health Corp (NASDAQ:PAHC) posted its quarterly earnings data on Monday, November, 4th. The company reported $0.19 EPS for the quarter, missing analysts' consensus estimates of $0.24 by $0.05. The firm earned $190 million during the quarter, compared to analyst estimates of $199.22 million. Phibro Animal Health had a net margin of 4.99% and a return on equity of 25.52%. The company's revenue for the quarter was down 5.0% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.39 earnings per share. View Phibro Animal Health's Earnings History.

Phibro Animal Health is scheduled to release their next quarterly earnings announcement on Monday, February 3rd 2020. View Earnings Estimates for Phibro Animal Health.

Phibro Animal Health will be holding an earnings conference call on Monday, February 3rd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Phibro Animal Health issued an update on its FY20 earnings guidance on Monday, November, 4th. The company provided earnings per share guidance of $1.08-$1.14 for the period, compared to the Thomson Reuters consensus estimate of $1.12.

5 brokers have issued 12 month price objectives for Phibro Animal Health's stock. Their forecasts range from $18.00 to $42.00. On average, they anticipate Phibro Animal Health's share price to reach $26.60 in the next twelve months. This suggests a possible upside of 3.3% from the stock's current price. View Analyst Price Targets for Phibro Animal Health.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Phibro Animal Health in the last year. There are currently 2 sell ratings, 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Phibro Animal Health.

Media coverage about PAHC stock has been trending somewhat positive on Thursday, InfoTrie reports. The research firm identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Phibro Animal Health earned a coverage optimism score of 0.8 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Phibro Animal Health.

Phibro Animal Health saw a increase in short interest in December. As of December 31st, there was short interest totalling 778,200 shares, an increase of 7.1% from the December 15th total of 726,300 shares. Based on an average daily volume of 171,600 shares, the short-interest ratio is currently 4.5 days. Approximately 3.9% of the shares of the company are sold short. View Phibro Animal Health's Current Options Chain.

Some companies that are related to Phibro Animal Health include Allakos (ALLK), United Therapeutics (UTHR), Nektar Therapeutics (NKTR), Blueprint Medicines (BPMC), FibroGen (FGEN), SAGE Therapeutics (SAGE), Mirati Therapeutics (MRTX), GW Pharmaceuticals PLC- (GWPH), Deciphera Pharmaceuticals (DCPH), PTC Therapeutics (PTCT), Ultragenyx Pharmaceutical (RARE), HUTCHISON CHINA/S (HCM), Taro Pharmaceutical Industries (TARO), Intercept Pharmaceuticals (ICPT) and Myokardia (MYOK).

Based on aggregate information from My MarketBeat watchlists, some companies that other Phibro Animal Health investors own include Zynga (ZNGA), Trevena (TRVN), Endo International (ENDP), Intercept Pharmaceuticals (ICPT), Sonoma Pharmaceuticals (SNOA), Zynerba Pharmaceuticals (ZYNE), Zoetis (ZTS), Booking (BKNG), Banco Bradesco (BBD) and Gilead Sciences (GILD).

Phibro Animal Health's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Tocqueville Asset Management L.P. (0.70%) and Nisa Investment Advisors LLC (0.07%). Company insiders that own Phibro Animal Health stock include Bfi Co, Llc, Daniel M Bendheim, Dean J Warras, E Thomas Corcoran, Jack Bendheim and Larry Lee Miller. View Institutional Ownership Trends for Phibro Animal Health.

PAHC stock was purchased by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC and Tocqueville Asset Management L.P.. View Insider Buying and Selling for Phibro Animal Health.

Shares of PAHC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PAHC stock can currently be purchased for approximately $25.76.

Phibro Animal Health has a market capitalization of $1.04 billion and generates $828 million in revenue each year. The company earns $54.71 million in net income (profit) each year or $1.53 on an earnings per share basis. Phibro Animal Health employs 1,600 workers across the globe.View Additional Information About Phibro Animal Health.

The official website for Phibro Animal Health is http://www.pahc.com/.

Phibro Animal Health's mailing address is GLENPOINTE CENTRE EAST 3RD FLOOR 300 FRANK W. BURR BLVD. SUITE 21, TEANECK NJ, 07666. The company can be reached via phone at 201-329-7300 or via email at [email protected]